Search results for "Prostate Cancer"
Benefit of PSA screening diminished in an analysis of ERSPC data using QALYs
A new analysis quantified the effects of prostate-specific antigen (PSA) screening on men's quality of life.
https://immattersacp.org/weekly/archives/2012/08/21/4.htm
21 Aug 2012
Metastatic disease reduced in PSA screening era, study indicates
Prostate-specific antigen (PSA) screening reduced the number of men presenting with metastatic prostate cancer, a new study found.
https://immattersacp.org/weekly/archives/2012/08/07/2.htm
7 Aug 2012
Tailor prostate screening based on life expectancy, ASCO recommends
A provisional clinical opinion from the American Society of Clinical Oncology (ASCO) recommends against prostate-specific antigen screening for men with a life expectancy of 10 years or less.
https://immattersacp.org/weekly/archives/2012/07/24/2.htm
24 Jul 2012
USPSTF recommends against prostate-specific antigen screening
The U.S. Preventive Services Task Force (USPSTF) released its final recommendations on prostate-specific antigen (PSA) screening today, recommending against using the test for prostate cancer screening in men of all ages in the general population.
https://immattersacp.org/weekly/archives/2012/05/22/1.htm
22 May 2012
European study finds prostate cancer mortality reduced by PSA screening
Prostate-specific antigen (PSA)-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality, according to two more years of follow-up results in the European Randomized Study of Screening for Prostate Cancer.
https://immattersacp.org/weekly/archives/2012/03/20/4.htm
20 Mar 2012
Too much or too little selenium associated with higher mortality
Selenium supplements are beneficial to people with low levels of the mineral, but those with levels over 122 µg/L do not obtain improvement in mortality or other outcomes from supplementation, according to a new review of available studies on selenium.
https://immattersacp.org/weekly/archives/2012/03/06/5.htm
6 Mar 2012
Information plus documentation a must for informed consent
Documentation of informed consent is an important deterrent to malpractice and negligence claims. One physician describes how his informed consent process was the deciding factor in a missed case of prostate cancer, and outlines how any physician can accomplish it.
https://immattersacp.org/archives/2012/01/consent.htm
1 Jan 2012
CONFERENCE COVERAGE Information plus documentation a must for informed ...
In 1990, Dr. Gottesman was sued forlate diagnosis of a patient’s prostate cancer.He won the case, and one of the jurors toldhim that the deciding factor had beeninformed consent ... documentation showingthat the patient had been warned that abiopsy could miss cancer.
https://immattersacp.org/archives/2012/01/acpi-201201-coding_t4.pdf
19 Dec 2011
NIH panel advocates delaying treatment for low-grade prostate cancer
Men with localized, low-risk prostate cancer should be closely monitored until disease progression warrants treatment, concluded an independent panel of the National Institutes of Health.
https://immattersacp.org/weekly/archives/2011/12/13/1.htm
13 Dec 2011
Model predicts erectile function after prostate cancer
Researchers have developed a new model to predict the risk of erectile dysfunction for men undergoing prostate cancer treatment.
https://immattersacp.org/weekly/archives/2011/09/27/4.htm
27 Sep 2011